Catalyst

Slingshot members are tracking this event:

Ionis Pharmaceuticals (IONS) Reports Clinical Data from IONIS-ANGPTL3-L Rx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
IONS Community voting in process

Additional Information

Additional Relevant Details
Subjects who received multiple doses of 10 mg, 20 mg, 40 mg, or 60 mg of IONIS-ANGPTL3-LRx achieved dose-dependent, statistically significant mean reductions at Day 37 in ANGPTL3 of up to 83 percent (p ≤0.001).  These subjects also experienced statistically significant mean reductions in triglycerides of up to 66 percent (p ≤0.001), in LDL-C of up to 35 percent (p ≤0.001), and in total cholesterol of up to 36 percent (p ≤0.001).  In this study, IONIS-ANGPTL3-LRx displayed a favorable safety and tolerability profile.  There were no discontinuations due to adverse events and no clinically meaningful platelet declines.
http://ir.ionispharm...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 15, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Angptl3, Elevated Triglycerides, Phase 1/2a Study, Nash, Lica Drugs, Ligand Conjugated Antisense (lica)